Osteocalcin Predicts BMD in Postmenopausal Women
METHODS: Eighty-two consecutive postmenopausal women with untreated osteoporosis were included in the study. Forearm, spinal, and femoral BMD by dual-energy x-ray absorptiometry and markers of bone formation (serum osteocalcin and bone-specific alkaline phosphatase) and bone resorption (urinary free deoxypyridinoline) were measured in all patients. Patients with low serum vitamin D levels, secondary osteoporosis, or clinically significant systemic disease were excluded from the study. The patients were classified on the basis of BMD of the lumbar spine into the following 3 groups: mild (n = 23) (T score -2.5 through -3), moderate (n = 42) (T score -3.1 through -4), or severe (n = 17) (T score
RESULTS: Serum osteocalcin was significantly different among the 3 study groups (4.1 +/- 2.7, 4.5 +/- 3.1, and 6.7 +/- 5.6 ng/mL, respectively; P = .0349) and had a significant negative correlation with BMD (r2 = -0.0779; P = .0168). Other bone markers such as bone-specific alkaline phosphatase and urinary free deoxypyridinoline did not correlate with the underlying BMD.
CONCLUSION: In our study, osteocalcin was significantly correlated with BMD in postmenopausal women with osteoporosis. Other bone markers did not correlate with BMD. Further large-scale population data and analyses are needed to confirm these findings.
Hari Kumar KV, Muthukrishnan J, Verma A, Modi KD.
Correlation between bone markers and bone mineral density in postmenopausal women with osteoporosis.
Department of Endocrinology, Medwin Hospitals, Hyderabad, India.